Cancer Gene Mutations Awaken the Immune System in Early Oral Cancer

Some of the very mutations that help cancer take hold may also sound the alarm that slows it down. In a study published in the journal Oncogene, researchers at Tokushima University in Japan report that specific combinations of mutations in two of the most frequently altered tumor suppressor genes in head and neck cancer, TP53 and CDKN2A, can trigger a powerful innate immune response during the earliest stages of oral carcinogenesis. That response, driven by the DNA-sensing cGAS–STING pathway, was associated with an influx of cytotoxic T cells and natural killer cells into developing lesions and, strikingly, with a delay in progression to invasive oral cancer in mice.

Head and neck squamous cell carcinoma, or HNSCC, is among the most common cancers worldwide, arising in the oral cavity and upper aerodigestive tract after chronic exposure to mutagenic forces such as tobacco smoke, alcohol, and betel nut. Alterations in TP53 and CDKN2A sit at the top of the list of genetic changes seen in these tumors, and they frequently occur together in the same malignancy. TP53 encodes the p53 protein, a master guardian of the genome that halts cell division when DNA damage is detected, while CDKN2A encodes components of the p16INK4A and p14ARF pathways that feed into retinoblastoma protein control of the cell cycle. Together, p53 and RB signaling form two of the central brakes on uncontrolled proliferation.

Despite how common these combined alterations are, their consequences during the earliest phases of tumor development have remained poorly understood. The research team, led by Ph.D. student Zichao Lu, Associate Professor Yasuhiro Mouri, and Professor Yasusei Kudo of the Department of Oral Bioscience at Tokushima University Graduate School of Biomedical Sciences, recognized a fundamental problem with the standard experimental toolkit. Conventional mouse models in which both genes are completely knocked out have not adequately reproduced human oral carcinogenesis. Moreover, in human patients these genes are not always fully disabled; partial activity may survive depending on the type and combination of mutations carried by a given tumor.

To build a model that better mirrors the human disease, the team generated mice carrying a human-relevant truncating mutation in Cdkn2a, corresponding to the R80X change seen in patients, and combined it with a loss-of-function alteration in Trp53, the mouse counterpart of TP53. The animals were then exposed to 4-nitroquinoline-1-oxide, or 4NQO, a carcinogen widely used to recapitulate the stepwise development of oral cancer in laboratory rodents. This system allowed the researchers to watch, stage by stage, how particular combinations of tumor suppressor damage reshape the oral epithelium under sustained carcinogenic stress, and how the surrounding immune microenvironment responds.

The results revealed a distinct and unexpected immune signature in the early lesions. Mice carrying the combined Trp53 and Cdkn2a alterations showed activation of the cGAS–STING–NF-κB axis, a signaling cascade that functions as a cellular alarm system for misplaced DNA. When the genome is destabilized, fragments of DNA can escape the nucleus and accumulate in the cytoplasm, where the enzyme cGAS detects them and activates STING, setting off NF-κB-driven inflammatory gene expression. In these early lesions, the imbalanced p53–RB signaling appears to create exactly this kind of genomic chaos, and the cell responds by switching on interferon-stimulated genes, inflammatory cytokines, and chemokines that recruit immune cells to the scene.

The cellular composition of the developing lesions shifted accordingly. The researchers observed increased infiltration of T cells and natural killer cells, along with a higher ratio of cytotoxic CD8-positive T cells to immunosuppressive regulatory T cells, a balance generally associated with productive antitumor immunity. Chemokines including Ccl3, Ccl4, and Ccl20 were elevated, providing molecular guidance cues that draw cytotoxic lymphocytes into the abnormal epithelium. The authors summarized the significance plainly: their study reveals that combinations of genetic alterations in TP53 and CDKN2A can shape the immune microenvironment during the early stages of oral carcinogenesis, rather than merely removing barriers to unchecked growth.

Crucially, this immune activation appeared to matter functionally. Mice with the combined alterations showed delayed progression to invasive oral cancer, suggesting that the cGAS–STING-driven inflammatory response acts as a brake on malignant advancement during early tumor development. To confirm that STING signaling was genuinely responsible rather than a passive byproduct, the team treated animals with H-151, a pharmacological inhibitor of STING. The inhibitor reduced interferon-related gene expression and decreased the infiltration of certain T-cell populations, providing direct evidence that the pathway contributes to the observed immune recruitment. As the authors put it, tumor-suppressor alterations do not simply promote cancer development; specific combinations of these alterations can also activate antitumor immunity during early carcinogenesis.

The immune landscape, however, did not stay favorable. As lesions progressed into full squamous cell carcinoma, T-cell infiltration declined across all genotypes, consistent with the emergence of a more immunosuppressive tumor microenvironment, the state that characterizes established cancers and undermines many immunotherapies. This transition suggests that the immune activation linked to particular TP53 and CDKN2A combinations is a feature of early carcinogenesis that fades as malignancy matures, raising the possibility that there is a limited window during which the antitumor response is active and potentially exploitable.

To ask whether the mouse findings translate to human disease, the researchers turned to The Cancer Genome Atlas HNSC cohort, a large collection of genomic and clinical data from patients with head and neck cancer. Combined TP53 and CDKN2A alteration patterns significantly separated overall survival, with distinct survival profiles associated with different genetic combinations. Yet the immune-activation signatures so prominent in the early mouse model were not clearly detectable in the human samples, which consisted predominantly of advanced-stage tumors. The discrepancy likely reflects disease stage rather than a failure of the underlying biology: by the time most patients reach surgical treatment, the early immune alarm has already been extinguished.

The clinical implications are nonetheless substantial. Oral potentially malignant lesions, such as leukoplakia, are currently assessed largely by histological appearance, and predicting which will progress to invasive cancer remains difficult. Combining TP53 and CDKN2A genetic status with measurements of immune activity within a lesion may eventually allow clinicians to stratify progression risk more precisely, identifying patients who need closer surveillance or earlier intervention while sparing others unnecessary treatment. The findings also suggest a rationale for therapeutic strategies that target the cGAS–STING pathway or immune checkpoints according to the genetic and immune characteristics of an individual tumor, although the authors caution that further studies are needed to establish optimal timing and clinical effectiveness in humans. Ultimately, they conclude, this knowledge may contribute to more precise risk assessment of oral precancerous lesions and to personalized prevention and treatment strategies built on both genetic alterations and the tumor immune microenvironment. The work reframes tumor suppressor mutations not as a simple binary of functional versus disabled genes, but as specific combinations of changes with the power to shape, for a time, the immune battlefield on which early cancer either advances or is held in check.

Subject of Research: How combined TP53 and CDKN2A tumor suppressor mutations activate cGAS–STING-mediated antitumor immunity during early oral carcinogenesis

Article Title: Tumor suppressor gene mutations trigger immune activation in early oral cancer

Article References: Tumor suppressor gene mutations trigger immune activation in early oral cancer. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: TP53, CDKN2A, cGAS–STING, oral cancer, head and neck squamous cell carcinoma, tumor suppressor genes, antitumor immunity, cytotoxic T cells, natural killer cells, carcinogenesis, tumor microenvironment, Oncogene